The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Tanespimycin is a new class of antineoplastic drugs Tanespimycin has demonstrated additive if not synergistic interaction with Velcade based MM txs Tanespimycin has a desirable iv infusion route of administration ( ROA)
Oncologists rely heavily on hormone and HER-2 status to guide treatment recommendations for women with breast cancer. If the results of these important tests are incorrect up to 20% of the time, we may be suboptimally treating many breast cancer patients.
Medical oncologists have "maxed out" on chemo combinations in lung cancer. It is clear that biologic agents need to be incorporated into our treatment regimens in order to move forward. Erbitux is safer and can be used in a broader population of lung cancer patients than Avastin.
Interleukin-21, or IL-21, is a protein that regulates immunomodulatory cell function. It appears to stimulate the activity of NK cells and cytotoxic T cells, which may be particularly relevant in targeting cancers that more responsive to the immune system, such as melanoma and renal cell carcinoma....
TLR9 Agonists have recently undergone phase III trials to improve outcome in lung cancer when combined with standard chemo TLR9 Agonists represents yet another attempt to demonstrate that the human cancer model is amendable to immunologic intervention
sutent has first line data supporting it's use in advanced REnal Cancer Sutent's cardiac problems, mainly CHF, will cause drug to loose market share Other TKI's and biologics of different actions will advance
Avastin has demonstrated PFS in first line metastatic breast cancer Avastin remains in a non approved status for breast cancer Avastin is very expensive and therefore scrutinized to the max
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...
Uveal melanoma, although similar histologically to the more common cutaneous melanoma, is virtually a completely different disease. Once metastatic, it has failed to respond to any form of systemic therapy, even those with some (albeit limited) efficacy in "standard" melanoma. Its relative rarity and...